Eagle Pharmaceuticals Inc (EGRX)
0.85
+0.05
(+6.25%)
USD |
OTCM |
Nov 07, 16:00
Eagle Pharmaceuticals Revenue (TTM): 257.55M for June 30, 2023
Revenue (TTM) Chart
Historical Revenue (TTM) Data
Date | Value |
---|---|
June 30, 2023 | 257.55M |
March 31, 2023 | 267.04M |
December 31, 2022 | 316.61M |
September 30, 2022 | 298.23M |
June 30, 2022 | 272.18M |
March 31, 2022 | 246.17M |
December 31, 2021 | 171.55M |
September 30, 2021 | 179.14M |
June 30, 2021 | 189.22M |
March 31, 2021 | 183.03M |
December 31, 2020 | 187.80M |
September 30, 2020 | 186.14M |
June 30, 2020 | 177.36M |
March 31, 2020 | 192.13M |
December 31, 2019 | 195.89M |
September 30, 2019 | 203.69M |
June 30, 2019 | 213.88M |
March 31, 2019 | 216.47M |
December 31, 2018 | 213.31M |
September 30, 2018 | 204.04M |
Date | Value |
---|---|
June 30, 2018 | 215.73M |
March 31, 2018 | 206.54M |
December 31, 2017 | 236.71M |
September 30, 2017 | 271.06M |
June 30, 2017 | 245.88M |
March 31, 2017 | 236.68M |
December 31, 2016 | 189.48M |
September 30, 2016 | 126.52M |
June 30, 2016 | 94.43M |
March 31, 2016 | 59.51M |
December 31, 2015 | 66.23M |
September 30, 2015 | 53.65M |
June 30, 2015 | 50.72M |
March 31, 2015 | 50.51M |
December 31, 2014 | 19.21M |
September 30, 2014 | 19.10M |
June 30, 2014 | 20.93M |
March 31, 2014 | 20.21M |
December 31, 2013 | 17.69M |
September 30, 2013 | 13.68M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
171.55M
Minimum
Dec 2021
316.61M
Maximum
Dec 2022
221.34M
Average
192.13M
Median
Mar 2020
Revenue (TTM) Benchmarks
Eli Lilly and Co | 40.86B |
Verrica Pharmaceuticals Inc | 9.21M |
NovaBay Pharmaceuticals Inc | 12.02M |
Palatin Technologies Inc | -- |
iBio Inc | -- |